Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity

Inclusion Criteria: * Prior participation in AFF008 and AFF008E * Written informed consent signed and dated by the patient and the caregiver (caregiver is not mandatory) * In the investigator's opinion, does not have visual or auditory impairments that would reduce the patients' ability to complete study questionnaires or be unable to receive instructions for these * Female patients of childbearing potential are eligible if they use a medically accepted contraceptive method * Stable doses of PD medications for at least 3 months prior to Visit 0 and during the entire trial period and of all other medications for at least 30 days prior to Visit 1 if considered relevant by the investigator Exclusion Criteria: * Women of childbearing potential without birth control or pregnant women * Participation in another clinical trial (except AFF008E) within 3 months before Visit 0 * History of questionable compliance to visit schedule; patients not expected to complete the clinical trial * Autoimmune disease or allergy to components of the vaccine * History of cancer (Exceptions: basal cell carcinoma, intraepithelial cervical neoplasia) * Active infectious disease * Immunodeficiency * Significant systemic illness or psychiatric illness * Alcoholism or substance abuse * Prior treatment with experimental immunotherapeutics for PD including IVIG (with the exception of AFFITOPE ® PD01A), with immunosuppressive drugs or treatment with deep brain stimulation * Venous status rendering it impossible to place an i.v. access